BiotechTube

PH-762

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Squamous Cell Carcinoma of the Skin

Conditions

Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin

Trial Timeline

Nov 7, 2023 → Mar 1, 2026

NCT ID
NCT06014086

About PH-762

PH-762 is a phase 1 stage product being developed by Phio Pharmaceuticals for Squamous Cell Carcinoma of the Skin. The current trial status is active. This product is registered under clinical trial identifier NCT06014086. Target conditions include Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin.

What happened to similar drugs?

4 of 20 similar drugs in Squamous Cell Carcinoma of the Skin were approved

Approved (4) Terminated (2) Active (14)
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅erlotinib [Tarceva]RocheApproved
✅erlotinib [Tarceva]RocheApproved
✅Platinum-based chemotherapy + Bevacizumab [Avastin]RocheApproved
🔄CT-P51 + EU-approved KeytrudaCelltrionPhase 3
🔄Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
🔄Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06014086Phase 1Active

Competing Products

20 competing products in Squamous Cell Carcinoma of the Skin

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
14
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
Cemiplimab + CetuximabEli LillyPhase 2
42
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
27
BB-401Benitec BiopharmaPhase 2
25
Ramucirumab + PaclitaxelEli LillyPhase 2
35
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
CT-P51 + EU-approved KeytrudaCelltrionPhase 3
47
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
47
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
39
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3
44
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
32
Avelumab + enfortumab vedotinAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
24
Drug Combination TherapySun PharmaceuticalPhase 2
42